Evidence map›Paper›PMID 25445336›Full record

ReviewVirus research2015

Receptor-binding domain-based subunit vaccines against MERS-CoV.

Naru Zhang, Jian Tang, Lu Lu, Shibo Jiang, Lanying Du

Open access · greenAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Virus research, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers.

0numbers the graph read from it
0cells of the map it votes in
47citing papers in PubMed
4.3field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

47 citing papers in PubMed, 62 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. A comprehensive insight on the COVID-19 vaccine candidates.Journal of family medicine and primary care · 2021
    Review
  5. Review
  6. Review
  7. Review
  8. Article
  9. Review
  10. 2020 update on human coronaviruses: One health, one world.Medicine in novel technology and devices · 2020
    Review
  11. Article
  12. Review
  13. Novel Coronavirus (nCoV): a Bitter Old Enemy in a New Avatar.SN comprehensive clinical medicine · 2020
    Review
  14. Review
  15. Review
  16. Article
  17. Article
  18. MERS coronavirus outbreak: Implications for emerging viral infections.Diagnostic microbiology and infectious disease · 2019
    Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 2 countries.

Naru ZhangLindsley F. Kimball Research Institute, New York Blood Center, New York, NY, USA.
Jian TangLindsley F. Kimball Research Institute, New York Blood Center, New York, NY, USA.
Lu LuKey Laboratory of Medical Molecular Virology of Ministries of Education and Health, Shanghai Medical College and Institute of Medical Microbiology, Fudan University, Shanghai, China.
Shibo JiangLindsley F. Kimball Research Institute, New York Blood Center, New York, NY, USA; Key Laboratory of Medical Molecular Virology of Ministries of Education and Health, Shanghai Medical College and Institute of Medical Microbiology, Fudan University, Shanghai, China. Electronic address: shibojiang@fudan.edu.cn.
Lanying DuLindsley F. Kimball Research Institute, New York Blood Center, New York, NY, USA. Electronic address: ldu@nybloodcenter.org.
New York Blood Center · USShanghai Medical College of Fudan University · CN

Funding

Critical neutralizing domain-based vaccines against new SARS-like virus hCoV-EMCR21AI109094 · NIAID · NEW YORK BLOOD CENTER · PI DU, LANYING · 2014 to 2015
$466k
NIAID NIH HHS R21 AI109094NIAID NIH HHS R21AI109094
6 · The paper itself

Abstract

Development of effective vaccines, in particular, subunit-based vaccines, against emerging Middle East respiratory syndrome (MERS) caused by the MERS coronavirus (MERS-CoV) will provide the safest means of preventing the continuous spread of MERS in humans and camels. This review briefly describes the structure of the MERS-CoV spike (S) protein and its receptor-binding domain (RBD), discusses the current status of MERS vaccine development and illustrates the strategies used to develop RBD-based subunit vaccines against MERS. It also summarizes currently available animal models for MERS-CoV and proposes a future direction for MERS vaccines. Taken together, this review will assist researchers working to develop effective and safe subunit vaccines against MERS-CoV and any other emerging coronaviruses that might cause future pandemics.

Indexed as

AnimalsCoronavirus InfectionsDrug DiscoveryHumansMiddle East Respiratory Syndrome CoronavirusVaccines, SubunitViral VaccinesVaccines, SubunitViral VaccinesMERS-CoVMiddle East respiratory syndrome coronavirusReceptor-binding domainSubunit vaccines

Identifiers

PMID25445336
PMCPMC4439384
OpenAlexW1995559179

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.